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The TNF family ligand ectodysplasin A (EDA) 
and its receptor EDAR are required for proper 
development of skin appendages such as hair, 
teeth and eccrine sweat glands. Loss of function 
mutations in the Eda gene cause X-linked 
hypohidrotic ectodermal dysplasia (XLHED), a 
condition that can be ameliorated in mice and 
dogs by timely administration of recombinant 
EDA. In this study, several agonist anti-EDAR 
monoclonal antibodies were generated that 
cross-react with the extracellular domains of 
human, dog, rat, mouse and chicken EDAR. 
Their half-life in adult mice was about 11 days. 
They induced tail hair and sweat gland 
formation when administered to newborn 
EDA-deficient Tabby mice, with EC50 of 0.1 to 
0.7 mg/kg. Divalency was necessary and 
sufficient for this therapeutic activity. Only 
some antibodies were also agonists in an in vitro 
surrogate activity assay based on the activation 
of the apoptotic Fas pathway. Activity in this 
assay correlated with small dissociation 
constants. When administered in utero in mice 
or at birth in dogs, agonist antibodies reverted 
several ectodermal dysplasia features, including 
tooth morphology. These antibodies are 
therefore predicted to efficiently trigger EDAR 
signaling in many vertebrate species and will be 
particularly suited for long-term treatments.  
 
The TNF family comprises 19 ligands, most of 
which control development, function and/or 
homeostasis of the immune system (1). In this 
respect, Ectodysplasin A (EDA) is an exception as 
it participates in ectodermal appendage formation 
(2). The Eda gene on the X chromosome is 
transcribed as multiple splice variants, only two of 
which code for the receptor-binding C-terminal 
TNF homology domain. These two variants, 
generated by splicing at an alternative donor sites 
between exons 8 and 9, code for 391 and 389 
amino acid-long proteins called EDA1 and EDA2 
(3). EDA1 binds the receptor EDAR, whereas 
EDA2 binds to another receptor, XEDAR (3). The 
    
 
 2 
biology of EDA2 and XEDAR is distinct from that 
of EDA1. Indeed, XEDAR-deficient mice have no 
obvious ectodermal dysplasia phenotype, whereas 
mice deficient in EDA, EDAR or the signaling 
adaptor protein EDARADD, all display virtually 
indistinguishable ectodermal dysplasia 
phenotypes, indicating the predominance of the 
EDA1 – EDAR axis in the development of skin-
derived appendages (4-8). 
In human, EDA1 loss of function mutations cause 
X-linked hypohidrotic ectodermal dysplasia 
(XLHED), a rare condition characterized by 
defective formation of teeth, hair, sweat glands 
and other glands (6). Because of their insufficient 
number of sweat glands, these patients are prone 
to hyperthermia. They also frequently suffer from 
recurrent respiratory tract infections caused by 
abnormal mucus production in the airways. Other 
problems are oligodontia, dry skin and dry eyes 
(9-11). 
EDA1 is a transmembrane Type II protein with a 
furin consensus cleavage site, a collagen-like 
domain and a C-terminal TNF homology domain, 
any of which when mutated can cause XLHED 
(12). In order to be active, EDA must be processed 
and bind EDAR through its trimeric C-terminal 
domain. The signaling ability of EDA1 is re-
enforced by its collagen domain that cross-links 
individual EDA1 trimers (13). Interestingly, some 
EDA1 mutations can also cause selective tooth 
agenesis, a condition characterized by no or very 
little involvement of other ectodermal appendages 
(14). In these patients, EDA1 mutants retain 
partial binding to EDAR, suggesting that tooth 
development is particularly sensitive to “high 
quality” EDAR signals. 
Transgenic expression of EDA1 in skin under the 
keratin 14 promoter results in a disheveled hair 
phenotype, hypertrophy of sebaceous glands and 
formation of supernumerary molars or nipples 
(15). Transgenic EDA1 expression in the skin of 
EDA-deficient Tabby mice corrected many of the 
ectodermal dysplasia defects (16). The reverted 
phenotype was stable even after shutdown of 
transgenic EDA1 expression in young adults, 
suggesting that EDA1 plays a role in the formation 
but not in the maintenance of skin appendages. 
Interruption of EDA1 expression however resulted 
in the normalization of sebaceous gland size (16). 
Similar conclusions were reached with an 
alternative approach of protein replacement 
therapy, in which EDA-deficient animals were 
exposed to a recombinant form of EDA during 
development (17,18). Taken together, these data 
provide a proof of concept for protein replacement 
therapy in young patients with XLHED. 
In this study, we generated agonist anti-EDAR 
antibodies that mimic the action of transgenic or 
recombinant EDA1 in development. Most of these 
antibodies cross-react with EDAR of mammals 
and birds and are active as monomeric, divalent 
molecules. They corrected, among others, sweat 
glands, tracheal glands and tooth morphology in 
EDA-deficient mice and were also active in EDA-
deficient dogs. These mouse monoclonal 
antibodies will be reagents of choice for long-term 
experiments in mice and pave the way for the 
development of therapeutic antibodies for use in 
XLHED or other EDAR-related applications in 
humans. 
 
EXPERIMENTAL PROCEDURES 
 
Animals - Mice were handled according to Swiss 
Federal Veterinary Office guidelines, under the 
authorization of the Office vétérinaire cantonal du 
canton de Vaud (authorization 1370.3 to PS). 
White-bellied agouti B6CBAa Aw-J/A-EdaTa/J 
Tabby mice (000314; Jackson Laboratory) were 
bred as  EdaTa/EdaTa and EdaTa/Y mutants, or as 
+/+ and +/Y wild type controls. EDAR-deficient 
OVE1B mice were as described (5). EDA-
deficient dogs (19) were cared for in accordance 
with the principles outlined in the National 
Institutes of Health Guide for the Care and Use of 
Laboratory Animals and in the International 
Guiding Principles for Biomedical Research 
Involving Animals. 
 
Plasmids and recombinant proteins - Plasmids 
used in this study were either previously 
published, or derived from the published plasmids 
by standard molecular biology techniques 
(13,20,21) (Fig. S1). A fully human form of Fc-
EDA1 was kindly provided by Dr Neil Kirby 
(EdimerPharma, Boston). hEDAR-Fc and 
mEDAR-Fc were produced and purified as 
described (21). 
 
Generation and purification of anti-EDAR 
monoclonal antibodies - 150 µg of hEDAR-Fc or 
mEDAR-Fc (amino acid residues 29-183. Fig. S1) 
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were briefly sonicated three times in 750 µl of 
PBS:STIMUNE (1:1, v/v) (Cedi-diagnostics, 
Lelystad, The Netherlands). Female OVE1B mice 
were immunized subcutaneously (base of tail, 200 
µl) with the antigen preparation, and boosted 
between days 10 to 14 with antigen in 
PBS:STIMUNE (base of tail, 150 µl). Mice 
positive for anti-EDAR antibodies at day 30 were 
boosted with 150 µg antigen in PBS at day 40 
(base of tail). Three days later, lymph node cells 
were fused with myeloma cells according to 
standard procedures, grown in complete RPMI 
medium over a feeder layer of mouse 
macrophages, and selected 24 h later with HAT 
(hypoxanthine, aminopterine and thymidine)-
containing medium. Supernatants of 96 wells 
plates were tested by ELISA for antibody 
secretion. Positive clones were subcloned twice by 
limiting dilution, and then slowly adapted to 
medium without macrophages and HAT 
supplement. Most hybridoma could then be 
progressively adapted to serum-free Opti-MEM 
medium (Invitrogen). Antibodies were purified 
from conditioned Opti-MEM supernatants by 
affinity chromatography on Protein G-Sepharose 
(GE Healthcare). 
 
Transfections - HEK 293T cells were grown in 
DMEM, 10% fetal calf serum and transfected by 
the calcium phosphate method. Cells were grown 
for 7 days in serum-free Opti-MEM medium 
(Invitrogen) for the production of EDAR-Fc 
truncation mutant fusion proteins, or for 48 h in 
complete medium for surface expression of 
receptors:TRAILR3 fusion proteins. 
 
ELISA - For the detection of anti-EDAR 
antibodies, ELISA plates were coated with 
hEDAR-Fc at 1 µg/ml, blocked and revealed with 
anti-EDAR antibodies (adequately diluted serum 
of EDAR immunized mice, hybridoma 
supernatants or purified antibody) followed by a 
peroxidase-coupled goat anti-mouse IgG (Jackson 
Immunoresearch). For isotype determination, 
ELISA plates were coated with 1 µg/ml of anti-
EDAR antibodies and revealed with peroxidase-
coupled antibodies against the heavy chain of 
mouse IgG1, IgG2a or IgG2b (SouthernBiotech). 
For epitope mapping, ELISA plates were coated 
with an Fab’2 fragment of a goat anti-human Ig 
(Jackson Immunoresearch) to capture various 
EDAR-Fc constructs or BCMA-Fc in cell 
supernatants. EDAR-Fc constructs and BCMA-Fc 
were revealed either with peroxidase-coupled 
donkey anti-human (H+L) (Jackson 
Immunoresearch), or with anti-EDAR antibodies 
at 1 µg/ml followed by peroxidase-coupled goat 
anti-mouse IgG (Jackson Immunoresearch), or 
with Flag-EDA1 or Flag-BAFF followed by 
biotinylated anti-Flag M2 antibody (Sigma) and 
peroxidase-coupled streptavidin. 
 
SDS-PAGE, Western blot, and native gel 
electrophoresis - Anti-EDAR antibodies (10 
µg/lane) were analyzed by SDS-PAGE under 
reducing conditions followed by Coomassie blue 
staining. Antibodies were also analyzed by native 
gel electrophoresis (4 µg/lane) (Biomidi, 
Toulouse, France) and stained with amidoblack 
according to manufacturer’s instructions, except 
that the electrophoresis was performed for 1 h.  
To test the ability of anti-EDAR antibodies to 
recognize denatured EDAR, 2 µg of bovine serum 
albumin, 20 ng of hEDAR-Fc and 20 ng of hFas-
Fc were analyzed by SDS-PAGE and western blot 
under reducing (100 mM dithiotreitol) or non-
reducing conditions, revealed with the various 
anti-EDAR antibodies at 1 µg/ml followed by 
peroxidase-coupled anti-mouse antibody 
(1:10000) and ECL reagent (GE Helathcare).  
 
Sequencing of anti-EDAR antibodies - RNA was 
extracted from hybridoma cells with an RNAeasy 
kit (Qiagen) according to manufacturer’s 
guidelines. cDNA was prepared by reverse 
transcription with Ready-To-Go T-Primed First-
Strand Kit (GE Healthcare). Variable sequences of 
the heavy and light chains were amplified by PCR 
as described (22). PCR products were sequenced 
on both strands. Sequences were analyzed for gene 
usage using the IMGT sequence alignment 
software (http://imgt.cines.fr/). 
 
FACS analyses - 293T cells co-transfected with 
EGFP and receptor-GPI expression plasmids were 
stained with Fc-EDA1 or Fc-EDA2 essentially as 
described before (20), or with anti-EDAR 
antibodies at 4 µg/ml followed by PE-coupled 
anti-mouse secondary antibody. Following 
staining, cells were analyzed using a FACScan 
flow cytometer (BectonDickinson) and FlowJo 
software (TreeStar, Ashland, OR).  
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Fab generation and affinity determination by 
surface plasmon resonance - An IgG1 Fab and 
Fab’2 preparation kit was used according to 
manufacturer’s instructions (Pierce). Briefly, 
purified anti-EDAR antibodies were digested for 
72 h at 37°C with immobilized ficin. Fc fragments 
and undigested antibodies were removed by 
chromatography on Protein A. The flow through, 
containing the Fab and Fab’2 fragments, was 
concentrated and applied onto a Superdex-200 gel 
permeation chromatography column eluted in 
PBS. Absorbance was recorded at 280 nm.  
For surface plasmon resonance, human EDAR-Fc 
was captured on anti-human IgG Fc-derivatized 
CM5 chips in a Biacore T100 (GE Healthcare). 
Fab solutions of anti-EDAR antibodies at the 
indicated concentration in PBS were applied for 
90 sec at 50 µl/min, and subsequently washed with 
buffer. All curve fittings were performed assuming 
a 1:1 binding model, although 2 antibodies had a 
biphasic dissociation that did not fit the 1:1 model.  
 
In vitro cytotoxicity assays - Fas-deficient 
hEDAR:Fas Jurkat cells have been described 
before, and mEDAR:Fas expressing cells were 
obtained by retroviral infection according to the 
same protocol (13). The cytotoxicity assay using 
EDAR:Fas Jurkat cells was performed as 
described for FasL on Jurkat cells (23). 
 
Injections in EDA-deficient animals - Tabby pups 
were labeled by puncture of a footpad with a 30-
gauge needle dipped in china ink. Intraperitoneal 
injections with anti-EDAR antibodies or Fc-EDA1 
were performed within 24 h after birth with a 
maximal volume of 15 µl, using 0.5 ml U-100 
insulin syringes (Becton Dickinson). Examination 
and photography of tail hairs were performed at 
days 20 to 22 post-injection. Pregnant Tabby mice 
were treated iv at days 13 and 20 (E13/E20) or 9 
and 17 (E9/E17) of gestation with 400 µg of anti-
EDAR antibody (antibody 3). Offspring were 
analyzed at 6 months of age, essentially as 
described (18). Age-matched wild-type and EDA-
deficient Tabby mice were similarly analyzed for 
comparison. Tracheal glands were detected by 
Alcian blue staining (24). Three dogs affected with 
X-linked ectodermal dysplasia were administered 
agonist anti-EDAR antibody 3 in the jugular vein 
at two days of live (n=2; 10 mg/kg) or at 14 days 
of live (n=1; 7 mg/kg). The analysis was 
performed essentially as described (17,25). In 
particular, the dogs were monitored daily for 
adverse reactions, overall health, and specific 
ocular and respiratory diseases. Complete blood 
cell counts and serum biochemistry screens were 
evaluated within 2 to 7 days after injection with 
agonist anti-EDAR antibody. Dental radiographs 
were obtained when the dogs were adults, when 
about one year old. Shirmer tear testing was 
performed at 6-month intervals. Complete 
necropsies were performed between 1.6 and 2.4 
years of age. Tissues were fixed in 10% neutral 
buffered formalin, routinely processed, sectioned 
at 5 µm and stained with hematoxilin and eosin.  
 
 
RESULTS 
 
Generation and screening of agonist anti-EDAR 
antibodies - To obtain cross-reacting antibodies 
against conserved EDAR regions, EDAR-deficient 
mice were immunized with either human or mouse 
EDAR-Fc fusion proteins. The EDAR-deficient 
mouse strains Downless and Sleek have loss-of-
function mutations in the extracellular or 
intracellular domains of EDAR, respectively, but 
still express the protein. We therefore immunized 
OVE1B mice in which the Edar gene is 
completely deleted by random genomic integration 
of an unrelated transgene (5,26). Hybridoma 
supernatants with anti-EDAR reactivity were 
screened for agonist activity using two 
complementary tests. In the first one, surrogate 
reporter cell lines stably expressing hEDAR:Fas or 
mEDAR:Fas fusion proteins were used. EDAR 
activation in these reporter cells leads to apoptotic 
cell death by activation of the Fas pathway (13). In 
the second assay, hybridoma supernatants were 
administered intra-peritoneally to newborn, EDA-
deficient Tabby pups (18). Tabby mice completely 
lack tail hairs, and the agonist activity of 
antibodies can therefore be measured by the 
induction of tail hair, provided that antibodies 
recognize and activate mouse EDAR. Several 
hybridoma secreted agonist antibodies with in vivo 
activity, but only few were also active in the cell-
based in vitro assay (data not shown). Selected 
hybridoma were subcloned and adapted for growth 
in serum-free medium from which antibodies were 
purified (Fig. 1A). The monoclonal nature of these 
    
 
 5 
antibodies was further confirmed by their sharp 
migration in native protein electrophoresis (Fig. 
1B).  
 
Agonist anti-EDAR antibodies have varied but 
relatively limited sequence characteristics - 
Variable regions of heavy and light antibody 
chains were amplified by RT-PCR and sequenced 
for several hybridoma. A number of different 
variable region genes were identified for both the 
heavy and light chains (Table 1), but some of them 
were shared by two or three hybridoma, usually 
with different somatic mutations. Interestingly, 
antibodies with identical heavy and light variable 
genes sharing greater than 90% sequence identity 
were obtained from different mice immunized 
with mouse (antibody 8) or human EDAR 
(antibodies 1 and 3) (Table 1, Fig. S2). Thus, 
different variable genes can be used to generate 
agonist anti-EDAR antibodies, but the gene 
repertoire must be limited as similar antibodies 
were found two or three times in the relatively 
limited panel that we have analyzed.  
 
Agonist antibodies recognize at least three 
different epitopes in EDAR - EDAR contains three 
cysteine-rich domains (CRD) in its extracellular 
region, plus a stalk sequence (Fig. 2A). We used 
EDAR constructs containing these four regions 
alone or in combinations to roughly characterize 
the epitopes recognized by the antibodies. Some 
antibodies recognized CRD1 alone, others 
recognized CRD1 and 2 together and one reacted 
with CRD1, 2 and 3, but none bound to receptors 
lacking CRD1 (Fig. 2B, Table 1). All antibodies 
recognized recombinant EDAR by Western blot 
under non-reducing conditions, but only three 
reacted with reduced EDAR (Fig. 2C). These three 
antibodies had their epitopes localized in CRD1. It 
is possible that the presence of CRD1 is required 
for correct folding of EDAR. Abnormal disulfide 
bridge formation in the absence of CRD1 would 
explain why antibodies did not recognize 
constructs containing CRD2 and CRD3. Taken 
together, these results indicate that agonist anti-
EDAR antibodies can recognize at least three 
different EDAR epitopes located in CRD1 and 
probably CRD2 and CRD3.  
 
Agonist anti-EDAR antibodies cross-react with 
EDAR of various mammals and birds  - Most anti-
EDAR antibodies cross-reacted with human, dog, 
rat, mouse and chicken EDAR when these were 
expressed as GPI-anchored molecules in 293T 
cells (Fig. 3). Antibody 5 only reacted minimally 
with chicken EDAR, whereas antibody 15 that had 
been selected on the basis of its specificity for 
human EDAR rather than for its agonist activity 
recognized human and dog EDAR, but not rat, 
mouse and chicken EDAR (Fig. 3). 
 
Binding characteristics of anti-EDAR antibodies 
to EDAR - The affinity of eleven agonist 
antibodies to human EDAR was determined by 
surface plasmon resonance. For this purpose, 
monomeric Fab fragments were generated by ficin 
digestion and size exclusion chromatography (Fig. 
4A). Affinities varied from 0.5 to 40 nM, and 
differences were also observed in the association 
and dissociation constants (Fig. 4B and Table 1). 
The dissociation kinetics of two antibodies (7 and 
14) were biphasic, showing first a rapid 
dissociation followed by a slower dissociation, but 
as these antibodies had no remarkable agonist 
activity, this was not analyzed further.  
 
Comparison of the activity of agonist anti-EDAR 
antibodies in vitro and in vivo - As we have not 
yet been able to identify a simple and quantitative 
assay to characterize EDAR agonists using 
EDAR’s own signaling pathway in vitro, we used 
a surrogate reporter assay in which Fas-sensitive 
cells were transfected with the extracellular 
domain of human or mouse EDAR fused to the 
intracellular portion of Fas. Binding of an active 
recombinant EDA1 (Fc-EDA1) to these cells 
induces cell death by activation of the pro-
apoptotic Fas pathway (13).  Interestingly, only 
some of the antibodies (1, 3, 8, 10 and 12) (Fig. 
5A) killed mEDAR:Fas expressing cells, and even 
fewer killed hEDAR:Fas expressing cells (1, 3, 10 
and 12) (Fig. 5B, Table 1). In all cases, antibodies 
were less active than Fc-EDA1 by one to two 
orders of magnitude. The picture was different in 
an in vivo assay, where newborn Tabby mice were 
treated with antibodies on the day of birth. In this 
case, all antibodies rescued tail hair formation in a 
dose-dependent manner and with similar EC50 of 
0.1 to 0.7 mg/kg (Fig. 6). Only one of the 
antibodies (antibody 11) seemed less active, with 
an EC50 of about 3 mg/kg.  Functional sweat 
glands were induced by the treatment with similar 
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EC50 as for tail hair (data not shown). The half-life 
of two antibodies (1 and 3) was determined in 
adult Tabby mice and found to be 10.5 and 11 
days, respectively (Fig. S3). 
 
Divalent monomeric agonist antibodies are active 
in vivo - We have shown previously that cross-
linked EDA1 containing more than one trimer in a 
single molecule are better agonists than trimeric 
EDA1 (13). We therefore wondered whether the in 
vivo activity of agonist anti-EDAR antibodies was 
due to monomeric antibodies or to aggregates 
thereof. The activity of a monomeric (divalent) 
antibody purified by size exclusion 
chromatography (Fig. 6, antibody 1) was however 
very similar to that of the total preparation (data 
not shown), and compared favorably (EC50 ~0.1 
mg/kg) with recombinant Fc-EDA1 (EC50 ~0.05 
mg/kg) (Fig. 6). In addition, the Fab’2 fragment, 
but not the Fab fragment, was active in vivo when 
administered in newborn pups on the day of birth 
(Fig. S4). When the Fab’2 was administered later 
at day 3 post-birth, one of the latest time points 
where ventral tail hair can be induced, its action 
could be inhibited by an excess of the Fab 
fragment, ruling out that the lack of agonist 
activity of the Fab would be due only to a shorter 
half-life in vivo (Fig. S4). We conclude from these 
observations that a divalent agonist anti-EDAR 
antibody is both sufficient and necessary to exert 
activity in Tabby mice.  
 
Effective treatment of EDA-deficient mice with 
agonist anti-EDAR antibodies - Some patients 
with partially inactivating EDA mutations have 
teeth defects but otherwise normal skin 
appendages, suggesting that tooth formation may 
require more stringent EDAR signals than other 
skin appendages for proper development (14). In 
order to test the effect of agonist antibodies on 
tooth development, pregnant Tabby mothers were 
treated during pregnancy so that the antibody 
could be transferred to embryos by the trans-
placental antibody transport system. Mice exposed 
to agonist anti-EDAR during development not 
only had tail hairs and functional sweat glands, but 
also hair behind the ears, mucus-secreting glands 
in the trachea and a normalized eye appearance 
(Fig. 7 A-G and Fig. S5). In addition molars of 
treated mice were reverted and almost 
indistinguishable from those of wild type animals 
(Fig. 7 H-I, Fig. S5). The effect was long-lasting, 
as a similarly treated mouse was still reverted after 
more than 2 years (Fig. S6). Taken together, these 
results indicate that the two agonists anti-EDAR 
antibodies tested in this application (1 and 3, Fig. 
7, S4 and data not shown) revert the ectodermal 
dysplasia phenotypes that we have looked at in 
Tabby mice, including tooth morphology. 
 
Activity of agonist anti-EDAR antibodies in EDA-
deficient dogs - Agonist anti-EDAR antibodies 
recognize EDAR of different species (Fig. 3). In 
order to test whether the observed cross-species 
reactivity also holds true for the agonist activity, 
anti-EDAR antibody 3 was administered 
intravenously to three EDA-deficient dogs at 
either 2 days of life (n=2, 10 mg/kg) or at 14 days 
of life (n=1, 7 mg/kg). None of these dogs showed 
adverse reactions upon injection. Dentition was 
corrected not only in EDA-deficient dogs that 
were treated at 2 days of life, but also in the 
affected treated at 14 days of life, although the 
latter still lacked premolars, accounting for the 
decreased number of teeth (Fig. 8 and Table 2).  
Interestingly, the premolars and molars in dogs 
treated at day 2 of life had a more normal 
appearance than in those dogs treated with Fc-
EDA (17). Lacrymation was improved in treated 
dogs except in one treated at day two of age (Table 
2). The correction of glands in trachea, bronchi 
and esophagus appeared however to be dependent 
on the age at which the dogs were treated: 
treatment administered earlier in life had a bigger 
impact on gland development (Fig. 8 and Table 2).  
It is noteworthy that, regardless of the extent of the 
phenotypic reversion, none of the treated dogs 
suffered from pneumonia or other airway diseases 
that are common in untreated EDA-deficient dogs, 
or from dry eye condition (keratoconjuctivitis 
sicca) that affect all XLHED dogs.  
 
DISCUSSION 
 
Deficiency in the TNF family ligand EDA leads to 
ectodermal dysplasia, even if the receptor EDAR 
remains fully functional. The development of 
EDAR agonists are thus of interest for applications 
in the treatment of XLHED. EDAR is relatively 
well conserved across species, with only 4 amino 
acid differences between human and dog, 10 
between human and mouse and 13 between human 
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and chicken in the 154 amino acid residues-long 
mature extracellular domain (Fig. S7). In order to 
increase the likelihood of getting cross-reactive 
antibodies, EDAR-deficient mice were used to 
generate monoclonal antibodies. The approach 
proved successful as 13 of the 15 anti-EDAR 
antibodies analyzed recognized EDAR from 
human, dog, rat, mouse and chicken. These 
antibodies are therefore likely to cross-react with 
EDARs of all mammals and many other 
vertebrates. Anti-EDAR15 differentiated human 
and dog from rat and mouse EDARs whose 
primary sequence only diverge in CRD1 (Fig. S7), 
implying that part of its epitope is in CRD1. Anti-
EDAR9 recognized CRD1, 2, and 3 of EDAR, but 
none of the CRDs taken individually or in pairs, 
despite the fact that these fragments were 
overlapping and supposed to respect structural 
elements of the receptor. These results indicate 
that EDAR may fold on itself to create a 
conformational epitope with regions that are 
distant in the primary sequence. In any case, 
results indicate that agonist anti-EDAR antibodies 
can recognize at least 3 distinct epitopes in EDAR. 
 
Anti-EDAR antibodies were screened in newborn 
Tabby mice, a highly relevant in vivo assay whose 
main limitation is to detect only antibodies cross-
reacting with mouse EDAR. More than half of the 
46 hybridoma supernatants tested were active in 
this assay, indicating that agonist antibodies can 
readily be obtained with the procedure used. The 
success rate of detection was however lower using 
the EDAR:Fas reporter cell lines that signal cell 
death in an oligomerization-sensitive manner, 
probably because these cell-based assays make use 
of a different intracellular signaling pathway. 
When combined, these assays discriminated two 
classes of agonist anti-EDAR antibodies, with or 
without in vitro activity. Interestingly, the in vitro 
activity correlated relatively well with low 
antibody dissociation constants, but not with 
association constants or affinities (Fig. S8). The 
EDAR:Fas reporter cells were previously shown to 
discriminate recombinant WT EDA1 and EDA1 
with the V365A mutation identified in a family 
with selective tooth agenesis, despite the fact that 
these two ligands bind EDAR-Fc almost equally 
well (14). This led to the hypothesis that formation 
of teeth may require higher quality EDAR signals 
than those needed for hair or gland formation. 
Thus, it is possible that agonist antibodies with 
activity in vitro may also be the best ones to 
correct tooth defects associated with EDA-
deficiency. It will be interesting to experimentally 
test this hypothesis in the future. 
 
The plethora of anti-EDAR agonist antibodies 
obtained, most of which were of the IgG1 isotype, 
was surprising. Indeed, there are indications that 
agonist anti-Fas antibodies (Fas is another TNFR 
family member) need to be oligomerized in order 
to be active. For example, the CH11 IgM 
monoclonal antibody directed against human Fas 
was obtained by immunization of mice with 
membranes of FS-7 human fibroblasts (27). When 
an IgG1 recognizing the exact same epitope (mAb 
ZB4) or a divalent Fab’2 of CH11 was used, there 
was no agonist activity (28). A second example of 
an agonist monoclonal antibody directed against 
human Fas is APO-1, which was obtained by 
immunizing mice with plasma membranes of the 
human SKW 6.4 cell line (29). This antibody is an 
IgG3. Upon isotype switch, it loses its agonist 
activity (30), a result that was tentatively 
explained by the propensity of IgG3 to self-
aggregate. As immunoglobulin preparations often 
contain low amounts of high molecular weight 
antibody aggregates (31), we wondered whether 
the agonist activity of anti-EDAR antibodies could 
be due to aggregates. This was however not the 
case as monomeric antibodies had a similar 
specific activity in vivo as the total preparation. In 
addition, a purified Fab’2 fragment was agonist in 
vivo, whereas the Fab fragment was not. We 
conclude that divalency is necessary and sufficient 
for anti-EDAR agonist antibodies to exert their 
activity. 
 
We have shown previously that the collagen 
domain of EDA oligomerizes the trimeric TNF-
homology domain of EDA1 into higher order 
structures with concomitant gain of activity (13). 
Similarly, Fc-EDA1 that assembles as a hexamer 
(containing two EDA1 trimers) is a highly active 
molecule. One interpretation is that multiple 
EDAR molecules must be recruited within the 
same complex in order to deliver robust 
intracellular signals, but this is in apparent 
contradiction with the observation that divalent 
antibodies are good agonists. A first hypothesis to 
reconcile these observations is that EDAR may 
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pre-exist as inactive complexes before ligand 
binding, as previously shown for Fas (32). Binding 
of a ligand may a) change the conformation of the 
complex to render it signaling competent and b) 
bring together two such complexes to initiate 
signaling. Divalent agonist antibodies may mimic 
hexavalent ligands by a) inducing the 
conformational change by binding one receptor in 
the pre-assembled complex and b) recruiting and 
activating a second complex on its second arm. In 
a second hypothesis, binding of the ligand or the 
antibody at an appropriate site of EDAR is 
sufficient to render the receptor signaling 
competent. Assembly of the signaling complex 
may however be relatively slow and reversible if 
the agonist detaches prematurely from the 
receptor. In this model, efficient signaling could 
be obtained either with divalent reagents with low 
dissociation constants, or with ligands that 
compensate relatively high dissociation constants 
by multivalency. Whatever their mechanism of 
action, Fc-EDA1 and agonist anti-EDAR 
antibodies are in practice excellent agonists to cure 
animal models of XLHED, including their teeth 
defects. Because of their long half-life in vivo, 
agonist anti-EDAR antibodies will prove useful 
reagents for long-term experiments, especially in 
mice where these mouse antibodies should elicit 
minimal neutralizing immune responses. 
 
Finally, it is noteworthy that keratoconjunctivitis 
sicca (dry eye) that affects all untreated EDA-
deficient dogs is believed to be caused by 
decreased tear production. Tear production 
improved significantly in two of the treated dogs 
but not in a third one (E237).  Nevertheless, none 
of the dogs treated in this study with agonist anti-
EDAR antibody required therapy for dry eye or 
any other ocular disorders. These findings suggest 
that decreased tear production is not the only 
factor causing dry eyes, but that other structures 
such as Meibomian glands that lubricate the eye, 
or the composition of the lipids therein, also play 
an important role. 
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FIGURE LEGENDS 
 
Fig. 1. Purity of protein-G purified anti-EDAR monoclonal antibodies. 
Anti-EDAR monoclonal antibodies were purified by protein G affinity chromatography from culture 
supernatants in serum-free medium (antibodies 1-4, 6-10, 12-14) or in serum-containing medium 
(antibodies 5, 11 and 15). 
Panel A. SDS-PAGE analysis and Coomassie blue staining of 10 µg antibody per lane under reducing 
conditions. Migration positions of molecular weight standards (in kDa) are shown. 
Panel B. Native gel electrophoresis of 4 µg anti-EDAR antibodies per lane, stained with amidoblack. 
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Fig. 2. Epitope mapping of anti-EDAR monoclonal antibodies. 
Panel A. Schematic linear representation of human EDAR showing the position of cystein residues (thin 
horizontal lines), of the putative N-linked glycosylation site (thick horizontal line, N) and of the six 
structural modules (rectangles with rounded corners) composing the three cystein-rich domains (CRD1, 
CRD2, CRD3). The transmembrane domain (TMD), signal peptide (Leader), stalk and intracellular 
domain (ID) are also shown. Amino acid numbers at the junctions of interest are indicated. The arrow 
indicates the predicted cleavage site of the signal peptide. The scheme is drawn to scale, except for the 
intracellular domain. 
Panel B. The indicated EDAR-Fc constructs or BCMA-Fc control were captured in an ELISA plate and 
revealed with the indicated anti-EDAR antibodies, or with an anti-human IgG to control efficient capture 
of the various EDAR-Fc proteins, or with Flag-EDA1 or Flag-BAFF as controls.  
Panel C. Bovine serum albumin (B; BSA, 2 µg), hEDAR-Fc (E, 20 ng) and hFas-Fc (F, 20 ng), were 
resolved by SDS-PAGE under reducing or non-reducing conditions, transferred onto nitrocellulose and 
probed with anti-EDAR 1 to 15. 
 
Fig. 3. Cross-species specificity of anti-EDAR antibodies. 
Receptors fused to the GPI anchor of TRAILR3 were expressed in 293T cells together with an EGFP 
tracer (x-axis) and stained with Fc-EDA1, Fc-EDA2 or with anti-EDAR antibodies (y-axis). Receptor 
expression was confirmed by staining with an antibody directed against the C-terminal portion of TRAIL-
R3 present in all constructs (mAb572). Both scattergram axes show fluorescence intensity on a 
logarithmic scale (100–104).  
 
Fig. 4. Generation and binding characteristics of anti-EDAR Fab fragments. 
Panel A. Superdex-200 gel permeation chromatography elution profiles of intact and ficin-digested anti-
EDAR antibodies. In the digested antibodies, Fc fragments and undigested antibodies were first removed 
by chromatography on Protein A. Peak identities are indicated. 
Panel B. Fab fragments at the indicated concentrations were analyzed by surface plasmon resonance onto 
immobilized hEDAR-Fc. Fab solutions were applied for 90 sec, and subsequently washed with buffer. 
Results for 3 antibodies with distinct binding characteristics are shown.  
 
Fig. 5. In vitro activity of anti-EDAR antibodies in a surrogate reporter assay. 
Panel A. Anti-EDAR antibodies and Fc-EDA1 were tested for their capacity to induce apoptosis of 
mEDAR:Fas-expressing Jurkat cells. After overnight culture, cell viability was determined by the 
PMS/MTS cell viability assay. EC50 are indicated as dotted lines. Anti-EDAR antibody number (or Fc-
EDA1) for each curve is indicated to the right of each panel. 
Panel B. Idem, except that hEDAR:Fas expressing cells were used.  
 
Fig. 6. Therapeutic doses of the anti-EDAR antibodies in newborn Tabby mice. 
Newborn Tabby mice were injected intra-peritonealy during the first 24 h of life with graded doses of 
anti-EDAR antibodies, an irrelevant mouse IgG1 (Aprily 5) or Fc-EDA1. Four to six weeks later 
(antibody 2, 3 and 4) or 3 weeks later (antibodies 1, 4 to 14 and Aprily5), hair density on the tail was 
scored according to the criteria shown in the insert. The anti-EDAR antibody 1 used in this experiment 
was the monomer peak obtained by gel filtration (see Fig. 4). 
 
Fig. 7. An anti-EDAR antibody reverts many ectodermal dysplasia phenotypes in EDA-deficient mice. 
Pregnant Tabby mice were treated iv at day 13 and 20 (E13/E20) of gestation with anti-EDAR antibody 3 
at 16 mg/kg. Offspring were analyzed at 6 months of age. Age-matched wild-type and EDA-deficient 
Tabby mice were similarly analyzed for comparison. 
Panel A. Tail phenotype. Panel B. Transversal sections of tail skin showing the presence of hair follicles, 
stained with hematoxylin and eosin. Panel C. Starch iodine sweat tests. Panel D. Sections of foot pads 
showing the presence of glandular structures of sweat glands (arrowheads), stained with hematoxylin and 
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eosin.  Panel E. Top view of the retro-auricular region showing the presence of hair behind the ears. Panel 
F. Sections of the trachea stained with Alcian blue to reveal mucus-secreting glands (arrowheads). Panel 
G. Eye phenotype showing reversion of the thickened eyelid margin and narrow eyelid opening. Panels H, 
I. Pictures of the jaw carrying the upper and lower molars. Antibody treated and wild type jaws carry 
larger teeth with a normal pattern of cusps on their surfaces. 
 
Fig. 8. An anti-EDAR antibody ameliorates dentition and presence of glands in EDA-deficient dogs. 
An EDA-deficient dog was treated at day 2 of live with a single dose of anti-EDAR (antibody 3) at 10 
mg/kg, and analyzed 1.6 years later in comparison with a wild type and with an affected dog. 
Panels A and B: Front and side views of the jaws. 
Panels C and D: Hematoxylin and eosin-stained tissue sections of the trachea and bronchi. Glandular 
tissues are indicated with arrowheads.  
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Table 1. Characteristics of anti-EDAR monoclonal antibodies. 
Anti- IGHV IGLV Anti- Iso- Epi- ka kd KD EC50 EC50 EC50 
EDAR gene gene Gen type tope M-1s-1 s-1 nM tail 
hair 
mEDAR
:Fas 
hEDAR:
Fas 
      * 10-5 * 104  mg/kg ng/ml ng/ml 
1 5-17 10-96 hu IgG1 I + II 6.79 3.69 0.54 0.125 10 200 
2 1-69 1-117 hu IgG1 I + II 13.2 13.3 1.00 0.42 >4000 >4000 
3 5-17 10-96 hu IgG1 I + II ND ND ND 0.18 30 100 
4 ND 1-117 hu IgG1 I + II 4.50 13.6 3.01 0.7 >4000 >4000 
5 2-2 4-91 hu IgG2b I ND ND ND 0.25 >4000 >4000 
6 1S135 1-110 hu IgG2a I 3.81 6.02 1.58 0.25 >4000 >4000 
7 7-3 4-577 hu IgG1 I + II 2.92 96.6 33.1 0.3 >4000 >4000 
8 5-17 10-96 mu IgG1 I + II 8.12 3.86 0.48 0.5 100 >4000 
9 1-63 1-117 mu IgG1 I+II+III 1.89 8.44 4.46 0.42 >4000 >4000 
10 1-39 4-55 hu IgG1 I + II 0.35 2.38 6.78 0.125 10 50 
11 1-39 10-94 hu IgG1 I + II ND ND ND 3.3 >4000 >4000 
12 1-14 17-12 mu IgG1 I 0.41 6.66 16.3 0.35 10 5 
13 1S135 1-110 hu IgG1 I 1.83 18.7 10.2 0.42 >4000 >4000 
14 1-42 10-94 mu IgG1 I + II 1.90 74.8 39.3 0.3 >4000 >4000 
15 1-63 12-44 hu IgG1 I + II ND ND ND ND ND ND 
 
IGHV, IGLV: immunoglobulin heavy and light chains variable region genes likely used in the antibody. 
hu: human EDAR-Fc. mu: Mouse EDAR-Fc. I + II: EDAR-Fc containing CRD1 and CRD2 of human 
EDAR. I: EDAR-Fc containing CRD1 only. Full: EDAR-Fc containing the full extracellular domain of 
EDAR. ka: association constant. kd: dissociation constant. KD: affinity of monomeric Fab to EDAR-Fc. 
EC50 tail hair: dose of antibody required to get half maximal tail hair reversion score when administered 
ip in newborn Tabby mice. EC50 mEDAR:Fas or hEDAR:Fas: dose of antibody required to kill half of 
the EDAR:Fas expressing Jurkat cells. 
 
Table 2. Summary of clinical and pathological findings in untreated XLHED dogs and XHLED dogs 
treated with anti-EDAR antibody 3. *day 14 or day 2 of life.  
 
Dog # Treatment 
protocol 
Age at 
necropsy 
Appearance of 
teeth (number) 
Tracheal 
glands 
Bronchial 
glands 
Esophageal 
glands 
Tear production 
        
Wildtype 
(n=5) 
 1-3 yrs Normal 
(41.6±0.9) 
+++ +++ +++ 97 ± 14% 
XLHED 
(n=6) 
 1-3 yrs Abnormal 
(18.0 ± 2.9) 
None None None 68 ± 20% 
E237 10 mg/kg 
on day 2* 
1.7 yrs Greatly 
improved (40) 
+++ +++ +++ 70.0 ± 4.1% 
E241 10 mg/kg 
on day 2* 
1.6 yrs Greatly 
improved (41) 
++ + ++ 90.0 ± 7.1% 
E222 7 mg/kg on 
day 14* 
2.4 yrs Improved (30) + - + 80.0 ± 27.1% 
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Supplemental Figure 1. List of plasmids used in the study. 
Amino acids are indicated with the one letter code or, for large stretches of sequence, by 
a written description. Signal (signal peptide of haemaglutinin: MAIIYLILLFTAVRG | ); 
Flag (DYKDDDDK); hEDA1, hEDA2 (SwissProt accession number Q92838); human, 
dog, rat, mouse, chicken EDAR (SwissProt accession numbers Q9UNEO, E2RA80, 
D3ZGP2, Q9R187 and Q5EFZ7); hFc (IgG1 encoded by GenBank accession number 
BC018747 or aa105-330 of SwissProt accession number P01857); hFas (SwissProt 
accession number P25445); Ig signal (Signal peptide of mouse Ig, heavy chain: 
MNFGFSLIFLVLVLKGVQC | EVKLV). The " | " indicate predicted proteolytic 
cleavage sites by signal peptidase. Sequences of interest were cloned into the mammalian 
expression vector PCR3 (Invitrogen) or into the retroviral expression vector pMSCV 
(Clonetech). Note that ps2765 and ps2783 were obtained by point mutations of the mouse 
and human sequences, respectively, and therefore are rat and dog sequences at the amino 
acid level only.  
 
Plasmid Designation Protein encoded Vector Figure
ps515 EGFP Enhanced green fluorescent protein PCR3 3
ps1938 Fc-EDA1 Signal-hIgG1 (aa 245-470)-hEDA1 (aa 238-391) PCR3 3, 5, 6
ps1377 pMSCV-puro Modified pMSCV-puro (Clonetech) with HindIII-BglII-EcoRI-
NotI-XhoI-HpaI-ApaI cloning sites
pMSCV
ps2199 hEDAR:Fas hEDAR (aa 1-183)-VD-hFas (aa 169-335) ps1377 5B
ps2260 mEDAR:Fas mEDAR (aa 1-183)-VD-hFas (aa 169-335) ps1377 5A
ps1235 Fc-EDA2 Signal-LD-hIgG1 (aa 245-470)-hEDA2 (aa 245-389) PCR3 3
ps1431 hEDAR-GPI hEDAR (aa 1-183)-VD-hTRAILR3 (aa 157-259) PCR3 3
ps2783 dogEDAR-GPI dogEDAR (aa 1-183)-VD-hTRAILR3 (aa 157-259) PCR3 3
ps2765 ratEDAR-GPI ratEDAR (aa 1-179)-VD-hTRAILR3 (aa 157-259) PCR3 3
ps1765 mEDAR-GPI mEDAR (aa 1-183)-VD-hTRAILR3 (aa 157-259) PCR3 3
ps2290 chEDAR-GPI chEDAR (aa 1-183)-VD-hTRAILR3 (aa 157-259) PCR3 3
ps548 Flag-EDA1 Signal-Flag-GPGQVQLQVD-mEDA1 (aa 245-391) PCR3 2
ps336 Flag-BAFF Signal-Flag-GPGQVQLQ-hBAFF (aa 137-285) PCR3 2
ps930 hEDAR-Fc hEDAR (aa 1-183)-VD-hIgG1 (aa 245-470) PCR3 2
ps2887 hEDAR (CRD1+2+3)-Fc hEDAR (aa 1-149)-VD-hIgG1 (aa 245-470) PCR3 2
ps2484 hEDAR (CDR1+2)-Fc hEDAR (aa 1-114)-VD-hIgG1 (aa 245-470) PCR3 2
ps2481 hEDAR(CRD1)-Fc hEDAR (aa 1-72)-VD-hIgG1 (aa 245-470) PCR3 2
ps2482 hEDAR (CRD2)-Fc Signal-LE-hEDAR (aa 71-114)-VD-hIgG1 (aa 245-470) PCR3 2
ps2524 hEDAR(CRD3)-Fc Signal-LE-hEDAR (aa 115-149)-VD-hIgG1 (aa 245-470) PCR3 2
ps2515 hEDAR(CRD2+3)-Fc Signal-LE-hEDAR (aa 71-149)-VD-hIgG1 (aa 245-470) PCR3 2
ps2508 hEDAR(CRD3+stalk)-Fc Signal-LE-hEDAR (aa 115-183)-VD-hIgG1 (aa 245-470) PCR3 2
ps2509 hEDAR(stalk)-Fc Signal-LE-hEDAR (aa 150-183)-VD-hIgG1 (aa 245-470) PCR3 2
ps815 mEDAR-Fc mEDAR (aa 1-183)-VD-hIgG1 (aa 245-470) PCR3 2
ps229 hFas-Fc hFas (aa1-170)-VDhIgG1 (aa 245-470) PCR3 2
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Supplemental Figure 2: Amino acid sequences of light and heavy chains variable 
regions of anti-EDAR monoclonal antibodies. 
Sequences start at the mature N-terminus. Complementarity determining regions (CDRs) 
are highlighted in boxes. Putative junctions of the protein sections encoded by the V, D 
and J genes, or by randomly added nucleotides (N) are indicated. The junction with the 
constant region (C) is also shown. Note that the light chains of anti-EDAR antibodies 2 
and 4 are identical, and the heavy chains of anti-EDAR antibodies 10 and 11 are 
identical. Anti-EDAR antibodies 1, 3 and 8 have similar heavy and light chains, most 
probably originating from the same VH and VL genes. 
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Supplemental Figure 3: Half-life determination of agonistic anti-EDAR antibodies. 
Wild type mice were intravenously injected with 200 !l of 1 mg/ml of anti-EDAR 1 or 
anti-EDAR 3 antibodies. Serum samples were collected after 20 minutes, 1, 2, 8, 16 and 
32 days. The concentration of the anti-EDAR mAb was determined by incubating serial 
dilutions of serum in wells coated with human EDAR-Fc at 1 !g/ml, followed by 
horseradish peroxidase-coupled anti-mouse IgG and OPD substrate. For analysis, the 
serum dilutions giving OD = 1 (considered to represent the EC50) for each time points 
were plotted as a function of time. An exponential curve was fitted on the series of points 
except the time point 20 minutes. A half-lives of 10 to 11 days were thus determined for 
anti-EDAR antibodies 1 and 3. 
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Supplemental Figure 4: An Fab’2 fragment of an agonist anti-EDAR antibody is active 
in vivo, whereas a monomeric Fab fragment acts as an inhibitor. 
A. Superdex-200 gel permeation chromatography elution profiles of ficin-generated Fab 
and Fab’2 fragments of anti-EDAR antibody 1, previously isolated by size exclusion 
chromatography (see Fig. 4A). Main peaks were collected and used for in vivo 
experiments. 
B. The Fab’2 fragment was injected at 0.5 mg/kg in newborn Tabby mice. Tail hair 
formation was recorded 3 weeks later. Administration of the Fab fragment at 4 mg/kg did 
not induce tail hair formation (n=3). 
C. The Fab’2 fragment was injected ip at 0.5 mg/kg in 3 days-old Tabby pups, which is 
one of the latest time point at which tail hair formation can still be partially rescued on 
the ventral side of the tail (on the left of the picture). The Fab fragment was injected at 4 
mg/kg 4 h before administration of the Fab’2 fragment and at 6 mg/kg together with the 
Fab’2 fragment. The Fab was then administered again at 10 mg/kg 24 and 48 h later.  Co-
treatment with the Fab fragment prevented the action of the Fab’2 fragment. 
 
 
 
Supplemental Figure 5: An anti-EDAR antibody reverts many ectodermal dysplasia 
phenotypes in EDA-deficient mice. 
A pregnant Tabby mouse was treated iv at day 9 and 17 (E9/E17) of gestation with anti-
EDAR 3 at 16 mg/kg. Offspring was analyzed at 6 months of age, as described in the 
legend to Figure 7. 
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Supplemental Figure 6: Long-term reversion of ectodermal dysplasia symptoms upon 
treatment with agonist anti-EDAR antibodies. 
A pregnant Tabby mouse was treated iv at day 13 (E13) of gestation with anti-EDAR 3 at 
6.5 mg/kg. Offspring and age-matched Tabby mouse were analyzed at 26 months of age.  
A. Tail. B. Tail tip, showing absence of a kink in the treated mouse. C. Back hair, 
showing the presence of the longer guard hair in the treated mouse. D. Sweat test 
showing the presence of functional sweat glands in the treated mouse (arrowhead). E. 
Retro-auricular region. F. Eye. 
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Supplemental Figure 7: Amino acid sequence of the mature extracellular domain of 
EDAR in different species. 
Divergent amino acids are highlighted with colours. The positions of the cystein-rich 
domains (CRDs) and stalk are indicated. 
 
 
 
Supplemental Figure 8: Correlation between low dissociation constants and agonist 
activity of anti-EDAR antibodies in an in vitro reporter cell line assay. 
Binding characteristics of the agonist anti-EDAR monoclonal antibodies (see Table 1) 
were plotted against their activity score in vivo (1/EC50, see Table 1) and their activity 
score in vitro. The activity score in vitro was determined as 8*(1/log(EC50 hEDAR)) + 
5.6*(1/log(EC50 mEDAR)) (see Table 1 for EC50 values). The correction factors 8 and 5.6 
were chosen so that the best antibody(ies) in the human or mouse EDAR:Fas assays 
score(s) 8 points. Antibodies showing agonist activity in vitro are identified by their 
numbers in the graphs. 
 
